Post-transplant cyclophosphamide demonstrates lower non-relapse mortality and better graft-versus-host disease/relapse-free survival compared with antithymocyte globulin in unrelated donor hematopoietic stem cell transplantation. A single-center experience

dc.contributor.author	Berro, Mariano.
dc.contributor.author	Rivas., M.
dc.contributor.author	Trucco, José.
dc.contributor.author	Et al.
dc.date.accessioned	2023-10-09T15:45:15Z
dc.date.available	2023-10-09T15:45:15Z
dc.date.issued	2021-04
dc.identifier.citation	Bone Marrow Transplant . 2021 Apr;56(4):986-988.	es
dc.identifier.issn	1476-5365
dc.identifier.uri	https://riu.austral.edu.ar/handle/123456789/2315
dc.description	Disponible en: https://www.nature.com/articles/s41409-020-01146-0	es
dc.description.abstract	Post-transplant cyclophosphamide demonstrates lower non-relapse mortality and better graft-versus-host disease/relapse-free survival compared with antithymocyte globulin in unrelated donor hematopoietic stem cell transplantation. A single-center experience	es
dc.language.iso	en	es
dc.publisher	Springer Nature	es
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 Internacional	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/	*
dc.subject	Post-transplant cyclophosphamide	es
dc.subject	Hematopoietic stem cell transplantation	es
dc.subject	Antithymocyte globulin	es
dc.title	Post-transplant cyclophosphamide demonstrates lower non-relapse mortality and better graft-versus-host disease/relapse-free survival compared with antithymocyte globulin in unrelated donor hematopoietic stem cell transplantation. A single-center experience	es
dc.type	Article	es

Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional